EGFR and non-small cell lung carcinoma: Currently, a phase II study is exploring the safety and efficacy of HER3-DXd as a single agent in EGFR-mutant NSCLC after progression on EGFR TKIs and one platinum-based chemotherapy-containing regimen (NCT04619004).